Article

Traumatic brain injury is a leading cause of morbidity and mortality in adults
and children in the United States. Despite steady improvement in our
understanding of the pathophysiology of acquired brain injuries, there has been
remarkably little improvement in brain injury therapies and/or pharmacologic
treatments over the past decade. One of the reasons may be the inability to
properly stratify subjects for clinical trials and/or to have real-time
assessment of the effectiveness of a given intervention. It has been recognized
for several decades that serum biomarkers may allow for more objective subject
stratification as well as act as surrogate markers of treatment efficacy. Despite
numerous studies, however, biomarkers are not currently part of clinical practice
in either acquired brain injury or other neurologic or musculoskeletal disorders.
The goals of this review article, therefore, are to use traumatic brain injury as
a example to discuss the use of biomarkers in clinical and randomized controlled
trials; to briefly discuss the field of neuroproteomics and its interface with
neurologic interventions; and to provide an overview of the collaborative pathway
between academia and industry, which needs to be an integral part of the
translation of biomarkers from the bench to the bedside in any clinical
population. Introduction of the concept of rehabilomics and implications of
biomarker use for the physical medicine and rehabilitation physician also are discussed.
CI - Copyright (c) 2011 American Academy of Physical Medicine and Rehabilitation.
Published by Elsevier Inc. All rights reserved.

Langue : ANGLAIS